Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
about
Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining ConditionsDual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsScreening for chronic comorbid diseases in people with HIV: the need for a strategic approachProteinuria in paediatric patients with human immunodeficiency virus infectionUpdate on current management of chronic kidney disease in patients with HIV infectionHIV and kidney diseases: 35 years of history and consequencesRole of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012Estimating kidney function in HIV-infected adults in Kenya: comparison to a direct measure of glomerular filtration rate by iohexol clearanceScreening for decreased glomerular filtration rate and associated risk factors in a cohort of HIV-infected patients in a middle-income countryIndividualizing pharmacotherapy in patients with renal impairment: the validity of the Modification of Diet in Renal Disease formula in specific patient populations with a glomerular filtration rate below 60 ml/min. A systematic reviewDevelopment and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D studyDrug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic StudyRisk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentLong-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeAbacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyKidney Disease and HIV Infection.Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposurePrevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in BrazilRelative risk of renal disease among people living with HIV: a systematic review and meta-analysis.Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study.The New Epidemiology of HIV-Related Kidney Disease.Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients.Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adultsA comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection.Recent developments in HIV-related kidney disease.Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real worldExpert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial.Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patientsWHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients.N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients.THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infectionDevelopment of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D studyChanges in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial
P2860
Q26740117-095D8F80-D7ED-4C09-BF56-5D0E94812658Q26768591-B07771D8-33AA-4EFF-8DB9-2F86A834271EQ26866452-BDED6654-4959-4208-897B-471BEE8513E8Q27009315-397C02D2-1E9A-4267-AAC8-C3FFA7B89810Q27691460-5BB536EA-BFC9-4411-9ED3-CC2170E2BA29Q28069641-32090E4D-9638-47C3-BEE2-8BDDB1E65F4CQ28533843-38866B66-FAD7-4CC2-8F50-BFD776586C7EQ28535213-F7A57956-FDEB-4189-85E1-842B9B064EC6Q28541930-E708DD9D-0EF7-4104-ABC1-BA59256A128CQ28543876-63A9875B-7BCA-440B-AA68-693C7E2647C7Q28545222-B8F470A0-AC10-4903-95C1-2A620A39057EQ28550681-4E814B30-D39D-43E6-912C-1C179286753DQ28554081-62B0F5AE-04CC-4934-8EA7-E1B58C651521Q28554567-85EDBB05-CCC0-42D3-AFF1-22F014D2E3EBQ28554630-219DC39E-C940-4FA2-8892-C8CAE0A0391FQ30234837-B56A9ABB-0FF4-4B1C-A153-AB15CBF8CC87Q30842348-41E60C61-D69F-4963-81C4-66A2B1E926BBQ33880241-8D4DE979-8E20-4FD1-AEA8-00106BEB48F9Q34055914-E51AA379-7AE3-4F19-85FD-7C5C84D78085Q34206774-BA0C456E-3F64-4077-8F6C-C4E03CAE81E3Q34271951-5360D24C-CD60-462B-A243-4F533F34A08FQ34307868-149E57F7-9306-4A03-9604-50C654A01C17Q34375843-90E9BD85-7047-4932-8722-8D399427124BQ34387456-C266699E-4AE3-4F43-BB3D-242B98C64915Q34495570-76C5CC22-FF6C-4851-A86E-9E061700826CQ34572458-9B5F8F6A-46A9-46ED-8D22-AEC7254B5D50Q34608823-E587FB8D-9CAB-405E-B169-1B2109BA7764Q34686870-F532169D-F17F-42DC-9E66-C2943DF67DEFQ34736194-10472289-377F-445B-87D3-160D1CD39427Q34736818-CFD327DE-7BDF-4D88-A9FD-F83D9DEB903CQ34787977-B8C9C8D2-E6EA-4A0B-B334-74C17C38A748Q34978897-BA5C9052-0E09-4B97-A124-6F4A69CAB5A2Q35018821-3D03AD6B-EE2B-468B-99BE-0E0747191892Q35040358-F38C0B96-D932-4164-86CD-74E56D92C751Q35040620-6AF716D8-EE52-46CB-AE10-02F38B825F4CQ35054462-2C61F7AA-48F4-4FE7-80D3-82799C8D84DCQ35071954-137BF775-37A4-46F0-B86A-587A03E5B6B6Q35091365-68A4D46B-76CA-44CC-AF1F-0C37B49A7766Q35130736-938B7ADB-ED9A-4BC3-9BDD-200486C0CF86Q35163040-C7AA99C3-8192-4F9E-AB52-CAF632C3D818
P2860
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Estimated glomerular filtratio ...... use in HIV-positive patients.
@en
Estimated glomerular filtratio ...... use in HIV-positive patients.
@nl
type
label
Estimated glomerular filtratio ...... use in HIV-positive patients.
@en
Estimated glomerular filtratio ...... use in HIV-positive patients.
@nl
prefLabel
Estimated glomerular filtratio ...... use in HIV-positive patients.
@en
Estimated glomerular filtratio ...... use in HIV-positive patients.
@nl
P2093
P50
P1433
P1476
Estimated glomerular filtratio ...... use in HIV-positive patients.
@en
P2093
Andrew N Phillips
Bruno Ledergerber
Dalibor Sedlacek
EuroSIDA Study Group
Jose Gatell
Marek Beniowski
Peter Reiss
Stephane De Wit
P304
P356
10.1097/QAD.0B013E328339FE53
P407
P577
2010-07-01T00:00:00Z